Unmet Need in Acute Immune-Inflammatory Disorders

Trauma is the leading cause of death in the US for individuals aged 1-44, while stroke is the third leading cause of mortality globally. Multiple clinical reports highlight that 40-50% of trauma related deaths occur 48 hours after the onset of the injury, and related to immune system related dysfunction. Likewise, compiled clinical data demonstrate that patients who survive the first 48 hours after stroke onset are more likely to die from immune related dysfunction. Collectively this immune condition has been recognized as cytokine release syndrome (CRS) or systemic inflammatory response syndrome (SIRS). This condition is poorly defined, and there are currently no options for identifying at risk patients, or directed therapeutic options for treating these patients.

Understanding Trauma-Associated Immune Pathogenesis and Utilization of Endogenous Treatment Mechanisms

CytoSage LLC, is a novel translational therapeutic company dedicated to the earliest identification of trauma patients at risk for progression to secondary immune-related dysfunction, as well as developing allogeneic cellular therapeutics for treatment of this same class of patients.

Targeting Secondary Developing Disorders

Following the onset of acute inflammatory conditions in patients, initiated by external severe traumatic injuries or internal pathological conditions such as acute stroke, clinical data suggests approximately 50% of these patients progress to more severe secondary immune mediated pathology such as ARDS, sepsis, acute kidney disease, acute lung injury, etc. Identifying which patients are likely to progress to these pathological conditions earlier would provide improved treatment options and patient outcomes.